2025
MAT2A inhibitor AG-270/S095033 in patients with advanced malignancies: a phase I trial
Gounder M, Johnson M, Heist R, Shapiro G, Postel-Vinay S, Wilson F, Garralda E, Wulf G, Almon C, Nabhan S, Aguado-Fraile E, He P, Romagnoli M, Hossain M, Narayanaswamy R, Sadou-Dubourgnoux A, Cooper M, Askoxylakis V, Burris H, Tabernero J. MAT2A inhibitor AG-270/S095033 in patients with advanced malignancies: a phase I trial. Nature Communications 2025, 16: 423. PMID: 39762248, PMCID: PMC11704051, DOI: 10.1038/s41467-024-55316-5.Peer-Reviewed Original ResearchConceptsAdvanced malignanciesEvidence of clinical activityPaired tumor biopsiesTreatment-related toxicityPhase I trialPhase 1 trialFirst-in-humanLiver function testsProof-of-mechanismHomozygous MTAP deletionPlasma SAM concentrationsPartial responseConcentrations of S-adenosylmethionineTumor biopsiesI trialSafety profileMTAP deletionHomozygous deletionMAT2A inhibitionClinical activityPlasma concentrationsFunction testsPatientsSecondary objectivesMaximal reduction
2018
ERBB Signaling Interrupted: Targeting Ligand-Induced Pathway Activation
Wilson FH, Politi K. ERBB Signaling Interrupted: Targeting Ligand-Induced Pathway Activation. Cancer Discovery 2018, 8: 676-678. PMID: 29858224, PMCID: PMC6330656, DOI: 10.1158/2159-8290.cd-18-0368.Commentaries, Editorials and Letters
2012
Administration of Vincristine in a Patient with Machado-Joseph Disease
Colpo A, Wilson FH, Nardi V, Hochberg E. Administration of Vincristine in a Patient with Machado-Joseph Disease. Oncology 2012, 82: 165-167. PMID: 22433430, PMCID: PMC3701890, DOI: 10.1159/000336602.Peer-Reviewed Original ResearchConceptsMachado-Joseph diseaseChemotherapy-induced peripheral neurotoxicityDose-limiting side effectVinca alkaloidsSevere vincristine neurotoxicityAdministration of vincristinePeripheral neurotoxicitySpinocerebellar ataxia type 3Vincristine neurotoxicityNeurological symptomsAtaxia type 3Side effectsHereditary neuropathyAntineoplastic drugsType 3NeurotoxicityDiseaseSignificant numberNeuropathyExacerbationPatientsVincristineSymptomsAdministration
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply